Stocktoria
SUTRO BIOPHARMA, INC. STRO
SUTRO BIOPHARMA, INC. financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102.5M | $62.0M | $153.7M | $67.8M | $61.9M | $42.7M | $42.7M | $38.4M | $51.7M |
| R&D expense | $166.4M | $252.0M | $180.4M | $137.2M | $104.4M | $77.0M | $65.6M | $54.3M | $54.6M |
| Operating income | -$158.4M | -$238.5M | -$89.3M | -$128.9M | -$98.5M | -$71.1M | -$55.5M | -$37.2M | -$19.3M |
| Interest expense | — | — | — | — | — | — | — | $1.6M | $612,000 |
| Income tax | -$93,000 | $2.4M | $18.2M | $2.5M | $0 | $103,000 | $0 | $0 | $0 |
| Net income | -$191.1M | -$227.5M | -$106.8M | -$119.2M | -$105.5M | -$32.1M | -$119.2M | -$35.3M | -$19.7M |
| EPS (diluted) | $-22.49 | $-29.40 | $-1.78 | $-2.35 | $-2.29 | $-0.99 | — | — | — |
| Operating cash flow | -$177.2M | -$191.5M | -$111.6M | $3.5M | -$81.7M | -$67.8M | -$65.0M | $12.7M | -$37.1M |
| Free cash flow | — | — | — | — | — | — | — | $11.1M | -$40.4M |
| Cash & equivalents | $58.1M | $190.3M | $69.3M | $47.3M | $30.4M | $206.2M | $5.0M | $125.3M | $22.0M |
| Total assets | $173.8M | $387.2M | $470.7M | $406.9M | $341.4M | $394.1M | $156.4M | $223.1M | $40.8M |
| Total liabilities | $306.3M | $342.6M | $321.1M | $189.9M | $88.8M | $62.1M | $58.6M | $91.6M | $47.3M |
| Shareholders' equity | -$132.5M | $44.6M | $149.6M | $217.0M | $252.6M | $332.0M | $97.8M | $131.5M | -$109.0M |
Growth · year-over-year · Revenue CAGR 8.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +65.2% | -59.6% | +126.8% | +9.5% | +44.8% | -0.0% | +11.2% | -25.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.